-
Financial statements audits
Financial statement audits
-
Compliance audits
Compliance audits
-
Compilations and reviews
Compilations and audit
-
Agreed-upon procedures
Agreed-upon procedures
-
Corporate and business tax
Our trusted teams can prepare corporate tax files and ruling requests, support you with deferrals, accounting procedures and legitimate tax benefits.
-
International tax
Our teams have in-depth knowledge of the relationship between domestic and international tax laws.
-
Tax compliance
Business Tax
-
Individual taxes
Individual taxes
-
Estate and succession planning
Estate and succession planning
-
Global mobility services
Through our global organisation of member firms, we support both companies and individuals, providing insightful solutions to minimise the tax burden for both parties.
-
Sales and use tax and indirect taxes
SUT/ VAT & indirect taxes
-
Tax incentives program
Tax incentives program
-
Transfer Pricing Study
The laws surrounding transfer pricing are becoming ever more complex, as tax affairs of multinational companies are facing scrutiny from media, regulators and the public
-
Business consulting
Our business consulting services can help you improve your operational performance and productivity, adding value throughout your growth life cycle.
-
Forensic and investigative services
At Grant Thornton, we have a wealth of knowledge in forensic services and can support you with issues such as dispute resolution, fraud and insurance claims.
-
Fraud and investigations
The commercial landscape is changing fast. An ever more regulated environment means organizations today must adopt stringent governance and compliance processes. As business has become global, organizations need to adapt to deal with multi-jurisdictional investigations, litigation, and dispute resolution, address the threat of cyber-attack and at the same time protect the organization’s value.
-
Dispute resolutions
Our independent experts are experienced in advising on civil and criminal matters involving contract breaches, partnership disputes, auditor negligence, shareholder disputes and company valuations, disputes for corporates, the public sector and individuals. We act in all forms of dispute resolution, including litigation, arbitration, and mediation.
-
Business risk services
We can help you identify, understand and manage potential risks to safeguard your business and comply with regulatory requirements.
-
Internal audit
We work with our clients to assess their corporate level risk, identify areas of greatest risk and develop appropriate work plans and audit programs to mitigate these risks.
-
Service organization reports
As a service organization, you know how important it is to produce a report for your customers and their auditors that instills confidence and enhances their trust in your services. Grant Thornton Advisory professionals can help you determine which report(s) will satisfy your customers’ needs and provide relevant information to your customers and customers’ auditors that will be a business benefit to you.
-
Transactional advisory services
Transactions are significant events in the life of a business – a successful deal that can have a lasting impact on the future shape of the organizations involved. Because the stakes are high for both buyers and sellers, experience, determination and pragmatism are required to bring deals safely through to conclusion.
-
Mergers and acquisitions
Globalization and company growth ambitions are driving an increase in M&A activity worldwide as businesses look to establish a footprint in countries beyond their own. Even within their own regions, many businesses feel the pressure to acquire in order to establish a strategic presence in new markets, such as those being created by rapid technological innovation.
-
Valuations
We can support you throughout the transaction process – helping achieve the best possible outcome at the point of the transaction and in the longer term.
-
Recovery and reorganization
We provide a wide range of services to recovery and reorganisation professionals, companies and their stakeholders.
For decades Puerto Rico has been known to be a significant player in the global manufacturing sector. Let’s look at what have been the facts and today’s current scenario.
During mid-August 2020, Puerto Rico received the visit of President Trump administration delegates: Dr. Peter Navarro, an economist and Assistant to the President, Director of the Office of Trade and Manufacturing Policy and Peter Brown, Federal Reconstruction Coordinator and Coast Guard Rear Admiral, currently serving as the Special Representative for Puerto Rico’s Disaster Recovery and other top leaders. They met with local government and business development representatives to review the island’s potential for the relocation of medical manufacturing plants that are currently located in China and India.
For several decades Puerto Rico has been known to be a significant player in the global pharmaceutical manufacturing sector mostly due to federal tax incentives that favored the development of the manufacturing industry in Puerto Rico. Those federal incentives date back to 1921 when US corporations and US citizens were exempted from federal taxes provided that they generated at least 80% of their gross income within a United States possession and at least 50% of such income was from an active trade or business conducted therein.
These incentives elapsed in 1996 when section 936 of the US Internal Revenue Code was repealed, although providing a 10-year partial grandfather. Current global disruptive events, such as the COVID-19 crisis, that has highlighted significant healthcare supply chains issues, and the current tense international environment involving trade laws and tariffs, particularly with China, have made the United States rethink its fiscal position on this regard.
We hereby discuss the two main tax policy trends that are under evaluation. But first, let us review what happened with Puerto Rico’s manufacturing industry after the termination of the incentives under section 936.
Most of the manufacturing facilities were converted into Controlled Foreign Corporations, the so-called CFCs. After concluding the federal tax preference to the US corporations with manufacturing activities in the US possessions, the tax strategy was to convert those US corporations into local corporations (i.e. a CFC), foreign for US tax purposes. By doing so, the federal taxation was deferred up to the moment of an actual distribution from the CFC to the US shareholder.
While Puerto Rico has been battling with the rest of the world to maintain and attract new manufacturing investments, other foreign jurisdictions, such as China, Singapore, and Ireland, among others, have emerged into the scenario. Even when the manufacturing sector in Puerto Rico has been reduced, the truth of the matter is that most of the big players in the global manufacturing sector have continued their presence in the island, although at a much lower capacity as their production is now distributed throughout several foreign countries.
This was the international regime until United States enacted a significant tax reform by the end of 2017, the Tax Cuts and Jobs Act. New federal tax rules applicable to foreign investments have stirred the international scenario because of their magnitude. Now, there are new players in the international federal tax law: the so-called GILTI and BEAT. GILTI (which stands for “global intangible low-taxed income”) created a new complex formula to tax CFCs profits earned in foreign jurisdictions that are highly profitable with low taxation.
A complex formula but with a simple result: CFCs net income over 10% of its net assets is considered ordinary income for the US shareholder. For its part, BEAT (the acronym for “base erosion anti-abuse tax”) is a new tax to be imposed on United States taxpayers when transacting with related entities in the foreign arena.
Currently, there are several bills introduced in the United States Congress that, if approved, would facilitate a much-needed transition for manufacturing facilities relocating to Puerto Rico. One proposes the establishment of Economically Distressed Zones, applicable to states as well as to US possessions and providing certain tax credits for wages and activities incurred in these zones. The second bill proposes, a preferential tax treatment for CFCs operating in US possessions by eliminating the GILTI.
On April 3, 2020, Congresswoman Jennifer González, resident Commissioner for Puerto Rico, introduced Bill HR 6643, the Securing National Supply Chain Act of 2020, to provide various tax credits to Economically Distressed Zones, including a tax credit on the amount of wages paid by an employer to employees in such a zone. The proposal also establishes a procedure for state and local government, including US possessions, to apply for designation as an Economically Distressed Zones based mostly on the poverty rate of the area. There would be a 10-year time frame to apply for the designation and, if obtained, the designation would be valid for a 15-year term. Moreover, the aforementioned credits would be increased if a manufacturing facility is moved to the US (including US possessions) from a foreign country that the US Trade Representative has determined could pose a risk to the national supply chain because of political or social factors.
On May 1, 2020, Congresswoman Stacey E. Plasket, representing the US Virgin Islands, filed Bill HR 6648 - the Territorial Economic Recovery Act, that if becomes law, it will exclude from the GILTI taxation the income earned by “qualified possession corporations” which are those that generate at least 80% of their gross income from sources within the possession and at least 75% of their income is from an active trade or business conducted therein.
A third bill presented on July 9, 2020 by Congresswoman González, HR 7527 – the Medical Manufacturing in Economically Distressed Zones, targets the medical manufacturing facilities engaging in research and development or production of medical products in the Economically Distressed Zones. The incentives included in this bill are similar to those of Bill HR 6643, that offer tax credits for wages paid and for depreciation and amortization of property used in the medical manufacturing facility.
The two main alternatives currently under evaluation to bring back manufacturing to the United States present different means to achieve the goal. One of them would protect specifically the corporations operating in US possessions from the anti-deferral impositions of GILTI brought by the US tax reform, while the other would provide a competitive scenario for all areas that may qualify as Economically Distressed Zones in the mainland as well as in the US possessions.
In any case, Puerto Rico has demonstrated a track record of reliability in manufacturing. The fact that Puerto Rico has been, for over 100 years, a global leader in manufacturing with the right ecosystem in place, proved highly skilled labor force, and demonstrated that large companies continue to have presence in the island should certainly incline the scale to choose Puerto Rico when reshoring pharma manufacturing. To quote Dr. Navarro and Brown’s words: “China fired, Puerto Rico hired!”